Skip to main content
SpringerLink
Log in

New approaches towards development, production and use of developing-country market vaccines in developing countries

  • Chapter
Book cover The Grand Challenge for the Future

Part of the book series: Birkhäuser Advances in Infectious Diseases BAID ((BAID))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Murphy TV, White KE, Pastor P, Gabriel L, Medley F, Granoff DM, Osterholm MT (1993) Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 269: 246–248

    Article  PubMed  CAS  Google Scholar 

  2. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD (1993) Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269: 221–226

    Article  PubMed  CAS  Google Scholar 

  3. Landaverde M, Di Fabio JL, Ruocco G, Leal I, de Quadros C (1999) Introduction of a conjugate vaccine against Hib in Chile and Uruguay. Rev Panam Salud Publica 5: 200–206

    PubMed  CAS  Google Scholar 

  4. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T (1999) Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four “newly adopting” countries. Vaccine 18: 736–742

    Article  PubMed  CAS  Google Scholar 

  5. Clemens JD, Jodar L (2004) Translational research to assist policy decisions about introducing new vaccines into developing countries. J Health Popul Nutr 22: 223–231

    PubMed  Google Scholar 

  6. Wenger J (2001) Vaccines for the developing world: current status and future directions. Vaccine 19: 1588–1591

    Article  PubMed  CAS  Google Scholar 

  7. Pan American Health Organization (2000) PAHO’s Revolving Fund Vaccine Prices for 2000. EPI Newsletter 22: 8

    Google Scholar 

  8. Batson A (1998) Win-win interactions between the public and private sectors. Nature Medicine,Vaccine Supplement 4: 487–491

    CAS  Google Scholar 

  9. Shinefield HR, Black S (2000) Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 19: 394–397

    PubMed  CAS  Google Scholar 

  10. Martin JF, Marshall J (2003) New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund. Vaccine 21: 587–592

    Article  PubMed  Google Scholar 

  11. Murasin W (2004) The global alliance for vaccines and immunization: is it a new model for effective public-private cooperation in international public health? Am J Public Health 94: 1922–1925

    Google Scholar 

  12. Plotkin SA (2002) Conclusions to the conference on orphan vaccines. Dev Biol 110: 167–169

    CAS  Google Scholar 

  13. Assessing the global needs for vaccine research and development. WHO/V&B/00.18 (available from WHO upon request)

    Google Scholar 

  14. Halstead SB, Deen J (2002) The future of dengue vaccines. Lancet 360: 1243–1245

    Article  PubMed  Google Scholar 

  15. Rabinovich NR (2002) Are we there yet? The road to a malaria vaccine. West J Med 176: 82–84

    PubMed  Google Scholar 

  16. Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30: 100–121

    PubMed  CAS  Google Scholar 

  17. Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM (2003) Meningococcal conjugate vaccine for Africa: A model for developing new vaccines for the poorest countries. Lancet 361: 1902–1904

    PubMed  Google Scholar 

  18. Finkelstein RA (1984) Cholera. In Germanier R (ed): Bacterial vaccines. Academic Press, Inc, New York, NY, 107–129

    Google Scholar 

  19. Robbins JB, Chu CY, Schneerson R (1992) Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the Ospecific polysaccharide of their lipopolysaccharides. Clin Infect Dis 15: 346–361

    PubMed  CAS  Google Scholar 

  20. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB (1994) Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12: 195–199

    Article  PubMed  CAS  Google Scholar 

  21. Coughlin RT, Fattom A, Chu C, White AC, Winston S (1995) Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine 13: 17–21

    Article  PubMed  CAS  Google Scholar 

  22. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC (1979) Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 140: 690–697

    PubMed  CAS  Google Scholar 

  23. Frasch CE (1994) Regulatory perspectives in vaccine licensure. In: Ellis RW, Granoff DM (eds): Development and clinical uses of Haemophilus influenzae type b conjugate vaccines. New York: Marcel Dekker, 435–453

    Google Scholar 

  24. Jodar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359: 1499–1450

    Article  PubMed  CAS  Google Scholar 

  25. Jodar L, Butler J, Carlone G, Dagan R, Frasch C, Goldblatt D, Kahty H, Klugman K, Plykaytis B, Siber G et al (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21: 3265–3272

    PubMed  CAS  Google Scholar 

  26. Robbins JB, Schneerson R, Szu SC, Fattom A, Yang Y, Lagergard T, Chu C, Sorensen US (1989) Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates. Curr Top Microbiol Immunol 146: 169–180

    PubMed  CAS  Google Scholar 

  27. Goldblatt D (1998) Immunisation and the maturation of infant immune responses. Dev Biol Stand 95: 125–132

    PubMed  CAS  Google Scholar 

  28. Ramsay ME, Andrews N, Kaczmarski EB, Miller E (2001) Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357: 195–196

    PubMed  CAS  Google Scholar 

  29. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22: 1087–1096

    Article  PubMed  CAS  Google Scholar 

  30. Paoletti LC, Kasper DL (2002) Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis 186: 123–126

    PubMed  Google Scholar 

  31. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins J et al (2001) The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to five-year old children. N Engl J Med 344: 1263–1269

    Article  PubMed  CAS  Google Scholar 

  32. Konadu EY, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB et al (2000) Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2-to 4-year-old children in Vietnam. Infect Immun 68: 1529–1534

    Article  PubMed  CAS  Google Scholar 

  33. Cryz SJ Jr, Cross AS, Sadoff JC, Wegmann A, Que JU, Furer E (1991) Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (OPS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 163: 1040–1045

    PubMed  CAS  Google Scholar 

  34. Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F et al (2001) Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 69: 1351–1357

    Article  PubMed  CAS  Google Scholar 

  35. Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, Szu SC (2000) Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun 68: 5037–5043

    Article  PubMed  CAS  Google Scholar 

  36. Chernyak A, Kondo S, Wade TK, Meeks MD, Alzari PM, Fournier JM, Taylor RK, Kovac P, Wade WF (2002) Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis 185: 950–962

    Article  PubMed  CAS  Google Scholar 

  37. WHO (1999) Pneumococcal vaccines. WHO position paper. Weekly Epidemiological Record 74: 177–183

    Google Scholar 

  38. WHO (1998) Hib vaccines. WHO position paper. Weekly Epidemiological Record 73: 64–71

    Google Scholar 

  39. WHO (1999) Meningococcal A and C vaccines. WHO position paper. Weekly Epidemiological Record 74: 297–304

    Google Scholar 

  40. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77: 651–666

    PubMed  CAS  Google Scholar 

  41. Black RE (1988) Overview of diarrheal diseases and strategies for their control. In: Holmgren J, Sack D (eds): New prospects for vaccines against diarrheal diseases. Swedish International Agency for Cooperation with Developing Countries, Stockholm, 47–59

    Google Scholar 

  42. WHO (2001) Cholera vaccines. WHO position paper. Weekly Epidemiological Record 76: 117–124

    Google Scholar 

  43. Ivanoff BN, Levine MM, Lambert PH (1994) Vaccination against typhoid fever: present status. Bull WHO 72: 957–971

    PubMed  CAS  Google Scholar 

  44. Webber D, Kremer M (2001) Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ 79: 735–741

    PubMed  CAS  Google Scholar 

  45. Herrera L (2001) Developing Country Manufacturers Network, GAVI Board Meeting, London (unpublished document)

    Google Scholar 

  46. Procedure for assessing the acceptability in principle of vaccines for purchase by United Nations agencies (WHO/VSQ/97.06)

    Google Scholar 

  47. The World Health Organization (1990) Requirements for diphtheria, tetanus, pertussis and combined vaccines. Technical report series, No. 500. Geneva 88–167

    Google Scholar 

  48. The World Health Organization (2000) Recommendations for the production and control of Hib conjugate vaccines. Technical report series, No. 897. Geneva 27–56

    Google Scholar 

  49. Jodar L, Griffiths E, Feavers I (2004) Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 22: 1047–1053

    PubMed  CAS  Google Scholar 

  50. Trach DD (1990) The problem of cholera vaccination in Vietnam. In: Sack D, Freij L (eds): Prospects for public health benefits in developing countries from new vaccines against enteric infections. SAREC Documentation, Stockholm, Conference Report 2, 217–218

    Google Scholar 

  51. AIDS vaccines (2000) IAVI issues blueprint to assure global access. AIDS Wkly 31: 23–25

    Google Scholar 

  52. Smith LA (2004) Bioterrorism: what level is the threat and are vaccines the answer? Expert Rev Vaccines 3: 493–495

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Vaccine Institute, SNU Research Park, San 4-8 Bongcheon-7-dong, Kwanak-gu, Seoul, Korea, 151-818

    Luis Jodar & John D. Clemens

Authors
  1. Luis Jodar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Clemens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max Planck Institute for Infection Biology, Schumannstrasse 21-22, D-10117, Berlin, Germany

    Stefan H.E. Kaufmann

  2. CMU — Centre of Vaccinology, 1 rue Michel Servet, CH-1211, Geneva 4, Switzerland

    Paul-Henri Lambert

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Jodar, L., Clemens, J.D. (2005). New approaches towards development, production and use of developing-country market vaccines in developing countries. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_4

Download citation

  • DOI: https://doi.org/10.1007/3-7643-7381-4_4

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-7643-7175-3

  • Online ISBN: 978-3-7643-7381-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation